1548 (1548) Fair Value & Analysis
Healthcare · Market cap HK$26.7B
Fair value as of: Jul 2, 2026
From 13 valuation models · updated today
Share price +8.3% over the past month.
Price vs Fair Value (12 months)
12‑month range HK$9.86 – HK$17.93 · fair‑value band HK$1.44 – HK$2.43 · the HK$12.23 price screens above the HK$1.93 fair value. As of Jul 2, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
1548 (1548) currently trades at HK$12.23, while our model-based Fair Value estimate is HK$1.93 — implying the stock looks roughly 84.2% overvalued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, 1548 generated revenue of HK$960M at a net margin of -55.5%. Revenue grew 42.5% year over year. It earns a return on equity of -12.9%. Net debt stands at HK$116M. Fundamentals as of Jul 2, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
1548 reported revenue of HK$960M in FY2025 versus HK$511M in FY2021, a compound +17.1%/yr. Reported net income was −HK$533M in FY2025.
Is 1548 fairly valued? → Check now
Recent news
- Genscript Biotech (SEHK:1548) Valuation Check After Recent Share Price Pullback
- DNA Synthesis Market to Reach $30.4 billion, Globally, by 2035 at 18.2% CAGR: Allied Market Research
- GenScript Sets New Benchmark for Responsible Biotech Leadership with 2025 ESG Report
- GenScript and Mimulus Partner to Industrialize DNA-Based Data Storage for the AI Era
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 5,617 MXN | -27% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is 1548 (1548) undervalued?
What is the fair value of 1548?
What is the quality score of 1548?
What is the revenue of 1548 (1548)?
What is the net profit margin of 1548?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.